首页> 外文期刊>Journal of receptor and signal transduction research >The BRET2/arrestin assay in stable recombinant cells: A platform to screen for compounds that interact with G protein-coupled receptors (GPCRS)
【24h】

The BRET2/arrestin assay in stable recombinant cells: A platform to screen for compounds that interact with G protein-coupled receptors (GPCRS)

机译:稳定重组细胞中的BRET2 / arrestin检测:筛选与G蛋白偶联受体(GPCRS)相互作用的化合物的平台

获取原文
获取原文并翻译 | 示例
           

摘要

In BRET2 (Bioluminescence Resonance Energy Transfer), a Renilla luciferase (RLuc) is used as the donor protein, while a Green Fluorescent Protein (GFP(2)) is used as the acceptor protein. In the presence of the cell permeable substrate DeepBlueC(TM), RLuc emits blue light at 395 nm. If the GFp(2) is brought into close proximity to RLuc via a specific biomolecular interaction, the GFp(2) will absorb the blue light energy and reemit green light at 510nm. BRET2 signals are therefore easily determined by measuring the ratio of green over blue light (510/395nm) using appropriate dual channel luminometry instruments (e.g., Fusion(TM) Universal Microplate Analyzer, Packard BioScience). Since no light source is required for BRET2 assays,the technology does not suffer from high fluorescent background or photobleaching, the common problems associated with standard FRET-based assays. Using BRET2, we developed a generic G Protein-Coupled Receptor (GPCR) assay based on the observation that activation of the majority of GPCRs by agonists leads to the interaction of beta-arrestin (a protein that is involved in receptor desensitization and sequestration) with the receptor. We established a cell line stably expressing the GFp(2): beta-arrestin 2 fusion protein, and showed that it can be used to monitor the activation of various transiently expressed GPCRs, in BRET2/arrestin assays. In addition, using the HEK 293/GFp(2): beta-arrestin 2 cell line as a recipient, we generated a double-stable line co-expressing the vasopressin 2 receptor (V2R) fused to RLuc (V2R: RLuc) and used it for the pharmacological characterization of compounds in BRET2/arrestin assays. This approach yields genuine pharmacology and supports the BRET2/arrestin assay as a tool that can be used with recombinant cell lines to characterize ligand-GPCR interactions which can be applied to ligand identification for orphan receptors. [References: None]
机译:在BRET2(生物发光共振能量转移)中,海肾荧光素酶(RLuc)用作供体蛋白,绿色荧光蛋白(GFP(2))用作受体蛋白。在细胞可渗透基质DeepBlueC TM的存在下,RLuc发射395nm的蓝光。如果通过特定的生物分子相互作用使GFp(2)与RLuc紧密接近,则GFp(2)将吸收蓝光能量并在510nm处重新发射绿光。因此,通过使用适当的双通道发光仪(例如,Fusion TM Universal Universal Plateplate Analyzer,Packard BioScience)测量绿色与蓝光的比率(510 / 395nm),可以容易地确定BRET2信号。由于BRET2分析不需要光源,因此该技术不会遭受高荧光背景或光漂白的困扰,而荧光漂白或光漂白是与基于标准FRET的分析相关的常见问题。使用BRET2,我们基于以下发现开发了一种通用的G蛋白偶联受体(GPCR)分析:激动剂激活大多数GPCR会导致β-arrestin(一种参与受体脱敏和螯合的蛋白质)与受体。我们建立了稳定表达GFp(2):β-arrestin2融合蛋白的细胞系,并显示了它可用于监测BRET2 / arrestin分析中各种瞬时表达的GPCR的激活。此外,使用HEK 293 / GFp(2):β-arrestin2细胞系作为受体,我们产生了一个双稳态细胞系,共表达与RLuc(V2R:RLuc)融合的血管加压素2受体(V2R),它可用于BRET2 / arrestin检测中化合物的药理学表征。这种方法产生了真正的药理作用,并支持BRET2 / arrestin分析作为一种可与重组细胞系一起用于表征配体-GPCR相互作用的工具,可将其应用于孤儿受体的配体鉴定。 [参考:无]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号